| Sequential therapy of refractory metastatic pancreatic cancer with 5‑FU/LV/irinotecan (FOLFIRI) vs. 5‑FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116) |
|
|
| J Cancer Res Clin Oncol 150(7): 332 |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1007/s00432-024-05827-x |
|
|
| Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial. |
|
|
| Oncol Res Treat 47 (suppl 1): 77-8 |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1159/000535363 |
|
|
| Alternating application of gemcitabine/nab-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): first results from the randomized phase 2 ALPACA Study from the German AIO study group (AIO-PAK-0114). |
|
|
| J Clin Oncol 42 (suppl 3) |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2024.42.3_suppl.605 |
|
|
| Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114) |
|
|
| Oncol Res Treat 47(6): 251-61 |
|
2024 |
|
Ösophagus-/Magenkarzinome
|
|
|
| doi.org/10.1159/000538143 |
|
|
| Safety and efficacy of everolimus (EVE) as second–line treatment in neuroendocrine neoplasms G3 (NEN G3) - an AIO phase II study (EVINEC) |
|
|
| Oncol Res Treat 47 (suppl 1): 236 |
|
2024 |
|
Neuroendokrine Tumoren
|
|
|
| doi.org/10.1159/000535363 |
|
|
| AIO-BNHO Comprehensive clinico-genomics database network (CONNECT, AIO-TF-0122) in Germany. |
|
|
| Oncol Res Treat 47(suppl 2): 201 |
|
2024 |
|
Molekulare und translationale Onkologie
|
|
|
| doi.org/10.1159/000540557 |
|
|
| mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: Discovery and validation of a gene expression signature in three randomized trials. |
|
|
| Ann Oncol 35 (Supplement 2, 581P): 471 |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.annonc.2024.08.650 |
|
|
| mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). |
|
|
| ESMO Open 9 (9) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.esmoop.2024.103703 |
|
|
| Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO. |
|
|
| Ann Oncol 35 (Supplement 2, 506O): 430-1 |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.annonc.2024.08.575 |
|
|
| Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212). |
|
|
| J Clin Oncol 41 (suppl 4) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.51 |
|
|
